Details about Alastair Gray

Access statistics for papers by Alastair Gray.

Last updated 2024-05-07. Update your information in the RePEc Author Service.

Short-id: pgr44

Working Papers

2015

1. Cost of poor adherence to anti-hypertensive therapy in five European countries
   Post-Print, HAL View citations (3)
   See also Journal Article Cost of poor adherence to anti-hypertensive therapy in five European countries, The European Journal of Health Economics, Springer (2015) View citations (2) (2015)

2013

2. Cost of Poor Adherence to Anti-Hypertensive Therapy in Europe
   CEIS Research Paper, Tor Vergata University, CEIS

2012

3. Wellbeing Over 50: A Capabilities Approach
   Open Discussion Papers in Economics, The Open University, Faculty of Social Sciences, Department of Economics

2004

4. Liability, insurance and defensive medicine: new evidence
   School of Economics Discussion Papers, School of Economics, University of Surrey

2003

5. Reducing Harm to Patients in the National Health Service. Will the Government’s Compensation Proposals Help?
   Briefing, Office of Health Economics View citations (1)

1988

6. Care in the community: a study of services and costs in six districts
   Working Papers, Centre for Health Economics, University of York
7. Staff turnover in the NHS: a preliminary economic analysis
   Working Papers, Centre for Health Economics, University of York View citations (2)

Journal Articles

2023

1. Prediction Models for Individual-Level Healthcare Costs Associated with Cardiovascular Events in the UK
   PharmacoEconomics, 2023, 41, (5), 547-559 View citations (1)

2022

2. Exploring Structural Uncertainty and Impact of Health State Utility Values on Lifetime Outcomes in Diabetes Economic Simulation Models: Findings from the Ninth Mount Hood Diabetes Quality-of-Life Challenge
   Medical Decision Making, 2022, 42, (5), 599-611

2021

3. Quality of life and associated factors among HIV positive patients after completion of treatment for Cryptococcal meningitis
   PLOS Neglected Tropical Diseases, 2021, 15, (3), 1-14

2020

4. Accurately Reflecting Uncertainty When Using Patient-Level Simulation Models to Extrapolate Clinical Trial Data
   Medical Decision Making, 2020, 40, (4), 460-473 View citations (3)

2019

5. A macroeconomic assessment of the impact of medical research expenditure: A case study of NIHR Biomedical Research Centres
   PLOS ONE, 2019, 14, (4), 1-10
6. Correction: A macroeconomic assessment of the impact of medical research expenditure: A case study of NIHR Biomedical Research Centres
   PLOS ONE, 2019, 14, (4), 1-1
7. The Challenge of Transparency and Validation in Health Economic Decision Modelling: A View from Mount Hood
   PharmacoEconomics, 2019, 37, (11), 1305-1312 View citations (3)

2018

8. Current UK Practices on Health Economics Analysis Plans (HEAPs): Are We Using Heaps of Them?
   PharmacoEconomics, 2018, 36, (2), 253-257 View citations (2)
9. Decision Making for Healthcare Resource Allocation: Joint v. Separate Decisions on Interacting Interventions
   Medical Decision Making, 2018, 38, (4), 476-486 View citations (1)
10. Risk attitudes of people with ‘manageable’ chronic disease: An analysis under prospect theory
    Social Science & Medicine, 2018, 214, (C), 144-153 View citations (6)

2017

11. Changing experience of adverse medical events in the National Health Service: Comparison of two population surveys in 2001 and 2013
    Social Science & Medicine, 2017, 195, (C), 83-89

2016

12. Economic evaluation of healthcare interventions: old and new directions
    Oxford Review of Economic Policy, 2016, 32, (1), 102-121 View citations (1)

2015

13. Cost of poor adherence to anti-hypertensive therapy in five European countries
    The European Journal of Health Economics, 2015, 16, (1), 65-72 View citations (2)
    See also Working Paper Cost of poor adherence to anti-hypertensive therapy in five European countries, Post-Print (2015) View citations (3) (2015)
14. Mapping from the Parkinson’s Disease Questionnaire PDQ-39 to the Generic EuroQol EQ-5D-3L
    Medical Decision Making, 2015, 35, (7), 902-911
15. Preferred Reporting Items for Studies Mapping onto Preference-Based Outcome Measures: The MAPS Statement
    PharmacoEconomics, 2015, 33, (10), 985-991 View citations (11)
    Also in Medical Decision Making, 2015, 35, (6), NP1-NP8 (2015) View citations (9)
    Applied Health Economics and Health Policy, 2015, 13, (5), 437-443 (2015) View citations (13)
16. Reply to comment on Cost of poor adherence to anti-hypertensive therapy in five European country
    The European Journal of Health Economics, 2015, 16, (8), 909-911 View citations (2)
17. The MAPS Reporting Statement for Studies Mapping onto Generic Preference-Based Outcome Measures: Explanation and Elaboration
    PharmacoEconomics, 2015, 33, (10), 993-1011 View citations (12)
18. Wellbeing over 50
    The Journal of the Economics of Ageing, 2015, 6, (C), 68-78 View citations (2)

2014

19. THE EFFECT OF DIABETES COMPLICATIONS ON HEALTH‐RELATED QUALITY OF LIFE: THE IMPORTANCE OF LONGITUDINAL DATA TO ADDRESS PATIENT HETEROGENEITY
    Health Economics, 2014, 23, (4), 487-500 View citations (18)

2013

20. Improving Clinical Reality in Chronic Obstructive Pulmonary Disease Economic Modelling
    PharmacoEconomics, 2013, 31, (2), 151-161 View citations (1)
21. Operationalising the capability approach for outcome measurement in mental health research
    Social Science & Medicine, 2013, 98, (C), 187-196 View citations (42)
22. PROFESSOR GAVIN MOONEY 1943–2012
    Health Economics, 2013, 22, (4), 371-372
23. The Impact of Risk Management Standards on Patient Safety: The Determinants of MRSA Infections in Acute NHS Hospitals, 2001–08
    Oxford Bulletin of Economics and Statistics, 2013, 75, (3), 340-361 View citations (12)

2012

24. A Systematic Review and Critical Assessment of Health State Utilities
    PharmacoEconomics, 2012, 30, (12), 1133-1143
    Also in PharmacoEconomics, 2012, 30, (12), 1133-1143 (2012)
25. Resource Use and Costs Associated with Coeliac Disease before and after Diagnosis in 3,646 Cases: Results of a UK Primary Care Database Analysis
    PLOS ONE, 2012, 7, (7), 1-12 View citations (1)

2010

26. Cost-Effectiveness of Pre-Referral Antimalarial, Antibacterial, and Combined Rectal Formulations for Severe Febrile Illness
    PLOS ONE, 2010, 5, (12), 1-12
27. Life Expectancy in Individuals With Type 2 Diabetes: Implications for Annuities
    Medical Decision Making, 2010, 30, (3), 409-414
28. Mapping the Modified Rankin Scale (mRS) Measurement into the Generic EuroQol (EQ-5D) Health Outcome
    Medical Decision Making, 2010, 30, (3), 341-354 View citations (3)

2009

29. From cost-effectiveness information to decision-making on liquid-based cytology: Mind the gap
    Health Policy, 2009, 89, (2), 193-200
30. Obesity as Market Failure: Could a ‘Deliberative Economy’ Overcome the Problems of Paternalism?
    Kyklos, 2009, 62, (2), 182-190 View citations (10)
31. The valuation of prenatal life in economic evaluations of perinatal interventions
    Health Economics, 2009, 18, (4), 487-494 View citations (2)

2007

32. Liability, insurance and medical practice
    Journal of Health Economics, 2007, 26, (5), 1057-1070 View citations (6)
33. Standard fees for legal aid: an empirical analysis of incentives and contracts
    Oxford Economic Papers, 2007, 59, (4), 662-681 View citations (2)

2006

34. Estimating the Association between SF-12 Responses and EQ-5D Utility Values by Response Mapping
    Medical Decision Making, 2006, 26, (1), 18-29 View citations (26)

2004

35. A longitudinal study of the effects of age and time to death on hospital costs
    Journal of Health Economics, 2004, 23, (2), 217-235 View citations (95)
36. Ageing and health‐care expenditure: the red herring argument revisited
    Health Economics, 2004, 13, (4), 303-314 View citations (111)
37. The Economics of Clinical Negligence Reform in England
    Economic Journal, 2004, 114, (496), F272-F292 View citations (6)

2002

38. Estimating Utility Values for Health States of Type 2 Diabetic Patients Using the EQ-5D (UKPDS 62)
    Medical Decision Making, 2002, 22, (4), 340-349 View citations (20)

2000

39. Centre‐specific or average unit costs in multi‐centre studies? Some theory and simulation
    Health Economics, 2000, 9, (3), 191-198 View citations (9)

1999

40. Professional Autonomy and the Cost of Legal Aid
    Oxford Economic Papers, 1999, 51, (3), 545-58 View citations (6)
41. The reform of Legal Aid in England and Wales
    Fiscal Studies, 1999, 20, (3), 261-286 View citations (10)

1998

42. Power and Sample Size Calculations for Stochastic Cost-Effectiveness Analysis
    Medical Decision Making, 1998, 18, (2_suppl), S81-S92 View citations (6)
43. The Use and Cost of HIV Service Provision in England in 1996
    PharmacoEconomics, 1998, 14, (6), 639-652 View citations (1)

1996

44. An exercise on the feasibility of carrying out secondary economic analyses
    Health Economics, 1996, 5, (2), 155-165
45. Labour turnover in the British National Health Service: a local labour market analysis
    Health Policy, 1996, 36, (3), 273-289 View citations (10)
46. The costs of nursing turnover: evidence from the British National Health Service
    Health Policy, 1996, 38, (2), 117-128 View citations (11)

1994

47. The Reform of Legal Aid
    Oxford Review of Economic Policy, 1994, 10, (1), 51-67 View citations (5)

1992

48. Forecasting the impact of demographic change: the case of the British National Health Service
    Health Policy, 1992, 20, (3), 269-275 View citations (2)

1982

49. The Production of Dental Care in the British National Health Service
    Scottish Journal of Political Economy, 1982, 29, (1), 59-74 View citations (4)

1980

50. Health Economics: A Review Article
    Scottish Journal of Political Economy, 1980, 27, (3), 297-304

1979

51. Programme budgeting in the health sector
    Omega, 1979, 7, (5), 451-458 View citations (3)

Books

2010

1. Applied Methods of Cost-effectiveness Analysis in Healthcare
   OUP Catalogue, Oxford University Press View citations (19)